[A case of therapy for bevacizumab-induced hypertension].
The patient was a 73-year-old female with sigmoid colon cancer, who underwent resection of sigmoid colon cancer and liver metastasis. She was treated with 5-fluorouracil and levofolinate calcium(sLV5FU2)plus bevacizumab(BV) for advanced colorectal cancer. She was treated with angiotensin II receptor blocker(ARB)because hersystolic blood pressure was 200 mmHg and her diastolic blood pressure 100 mmHg after five courses of BV therapy. As a result, her blood pressure was controlled. It was possible to administer BV. Therefore, ARB may be the preferred antihypertensive agent in the management of BV-induced hypertension.
Yasu
Takeo
T
Dept. of Pharmacy, Shonan Kamakura General Hospital, Japan.
Miyasaka
Yoshiyuki
Y
Chubachi
Hideo
H
Shimoyama
Rai
R
D000368:Aged; D057911:Angiotensin Receptor Antagonists; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D000068258:Bevacizumab; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000556:secondary; D011945:Receptors, Angiotensin / Q000378:metabolism; D012811:Sigmoid Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000601:surgery
D057911:Angiotensin Receptor Antagonists; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D011945:Receptors, Angiotensin; D000068258:Bevacizumab